Indications and uses
temporarily relieves minor aches and pains due to: minor pain of arthritis muscular aches backache menstrual cramps headache toothache the common cold temporarily reduces fever
temporarily relieves minor aches and pains due to: minor pain of arthritis muscular aches backache menstrual cramps headache toothache the common cold temporarily reduces fever
do not take more than directed the smallest effective dose should be used drink a full glass of water with each dose Adults and children 12 years and older take 1 tablet/caplet every 8 to 12 hours while symptoms last for the first dose you may take 2 tablets/caplets within the first hour do not exceed 2 tablets/caplets in any 8 to 12 hour period do not exceed 3 tablets/caplets in a 24-hour period Children under 12...
each tablet/caplet contains: sodium 20 mg store at 20-25°C (68-77°F). Avoid high humidity and excessive heat above 40°C (104°F).
PAIN RELIEVER / FEVER REDUCER (NSAID)
Drug Facts
Pain reliever/fever reducer
Allergy alert: Naproxen sodium may cause a severe allergic reaction, especially in people allergic to aspirin. Symptoms may include:
If an allergic reaction occurs, stop use and seek medical help right away.
Stomach bleeding warning: This product contains an NSAID, which may cause severe stomach bleeding. The chance is higher if you:
Heart attack and stroke warning: NSAIDs, except aspirin, increase the risk of heart attack, heart failure, and stroke. These can be fatal. The risk is higher if you use more than directed or for longer than directed.
Do not use
Ask a doctor before use if
Ask a doctor or pharmacist before use if you are
When using this product
Stop use and ask a doctor if
If pregnant or breast-feeding, ask a health professional before use. It is especially important not to use naproxen sodium at 20 weeks or later in pregnancy unless definitely directed to do so by a doctor because it may cause problems in the unborn child or complications during delivery.
Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away (1-800-222-1222).
| Adults and children 12 years and older |
|
| Children under 12 years |
|
FD &C Blue # 2, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polysorbate 80, povidone, talc, titanium dioxide
call toll-free weekdays 9 AM to 8 PM EST at 1-888-375-3784
Distributed by:
Dr. Reddy’s Laboratories, Inc.
Princeton, NJ 08540
Made in India
Rev: 03/2022
Caplets
Container
Container Carton
Tablets
Container
Container Carton
| Class | Version | Type | Effective |
|---|---|---|---|
| NAPROXEN Pharmacologic Class Indexing | 2 | Indexing - Pharmacologic Class | 20191108 |
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| fef6ad89-235f-4274-ba49-a8e53642473e | Product name | 2 | 20250225 |
| 87fed3e6-8fba-48ef-96b0-3a7fb54b96ff | Product name | 3 | 20230306 |
| b5fdaaec-7251-4da6-9cb2-4e9e76939ec8 | Product name | 1 | 20200623 |
| e76dbbc1-775d-722c-08ff-ed45e8a80def | Product name | 3 | 20181002 |
| 6f4f4521-fd56-1ae6-888b-3b021bd75c7c | Product name | 1 | 20140508 |
| ce67e27d-1d21-5465-4409-b0662dd99d4d | Product name | 1 | 20140508 |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 55111-272-01 | Naproxen Sodium | 100 in 1 BOTTLE | TABLET, COATED | 100 | 13 | |
| 55111-272-01 | Naproxen Sodium | 1 in 1 CARTON | TABLET, COATED | 1 | 13 | |
| 55111-272-02 | Naproxen Sodium | 1 in 1 CARTON | TABLET, COATED | 1 | 13 | |
| 55111-272-02 | Naproxen Sodium | 200 in 1 BOTTLE | TABLET, COATED | 200 | 13 | |
| 55111-272-05 | Naproxen Sodium | 500 in 1 BOTTLE | TABLET, COATED | 500 | 13 | |
| 55111-272-05 | Naproxen Sodium | 1 in 1 CARTON | TABLET, COATED | 1 | 13 | |
| 55111-272-24 | Naproxen Sodium | 24 in 1 BOTTLE | TABLET, COATED | 24 | 13 | |
| 55111-272-24 | Naproxen Sodium | 1 in 1 CARTON | TABLET, COATED | 1 | 13 | |
| 55111-272-50 | Naproxen Sodium | 50 in 1 BOTTLE | TABLET, COATED | 50 | 13 | |
| 55111-272-50 | Naproxen Sodium | 1 in 1 CARTON | TABLET, COATED | 1 | 13 | |
| 55111-273-01 | Naproxen Sodium | 100 in 1 BOTTLE | TABLET, COATED | 100 | 13 | |
| 55111-273-01 | Naproxen Sodium | 1 in 1 CARTON | TABLET, COATED | 1 | 13 | |
| 55111-273-02 | Naproxen Sodium | 1 in 1 CARTON | TABLET, COATED | 1 | 13 | |
| 55111-273-02 | Naproxen Sodium | 200 in 1 BOTTLE | TABLET, COATED | 200 | 13 | |
| 55111-273-05 | Naproxen Sodium | 500 in 1 BOTTLE | TABLET, COATED | 500 | 13 | |
| 55111-273-05 | Naproxen Sodium | 1 in 1 CARTON | TABLET, COATED | 1 | 13 | |
| 55111-273-24 | Naproxen Sodium | 1 in 1 CARTON | TABLET, COATED | 1 | 13 | |
| 55111-273-24 | Naproxen Sodium | 24 in 1 BOTTLE | TABLET, COATED | 24 | 13 | |
| 55111-273-40 | Naproxen Sodium | 400 in 1 BOTTLE | TABLET, COATED | 400 | 13 | |
| 55111-273-40 | Naproxen Sodium | 1 in 1 CARTON | TABLET, COATED | 1 | 13 | |
| 55111-273-50 | Naproxen Sodium | 50 in 1 BOTTLE | TABLET, COATED | 50 | 13 | |
| 55111-273-50 | Naproxen Sodium | 1 in 1 CARTON | TABLET, COATED | 1 | 13 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| Naproxen Sodium | ACTIVE INGREDIENT | 9TN87S3A3C | 3 | |
| Naproxen | ACTIVE MOIETY | 57Y76R9ATQ | 3 | |
| cellulose, microcrystalline | INACTIVE INGREDIENT | OP1R32D61U | 3 | |
| FD&C BLUE NO. 2 | INACTIVE INGREDIENT | L06K8R7DQK | 3 | |
| hypromelloses | INACTIVE INGREDIENT | 3NXW29V3WO | 3 | |
| magnesium stearate | INACTIVE INGREDIENT | 70097M6I30 | 3 | |
| polyethylene glycol | INACTIVE INGREDIENT | 3WJQ0SDW1A | 3 | |
| POLYSORBATE 80 | INACTIVE INGREDIENT | 6OZP39ZG8H | 3 | |
| povidone | INACTIVE INGREDIENT | FZ989GH94E | 3 | |
| talc | INACTIVE INGREDIENT | 7SEV7J4R1U | 3 | |
| titanium dioxide | INACTIVE INGREDIENT | 15FIX9V2JP | 3 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 55111-272 | 55111-272-24, 55111-272-50, 55111-272-01, 55111-272-02, 55111-272-05 |
| 55111-273 | 55111-273-24, 55111-273-50, 55111-273-01, 55111-273-02, 55111-273-40, 55111-273-05 |
Every source-derived ingredient row is available through these pages.
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| titanium dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | TABLET, COATED / ORAL | 49 mg | ||
| titanium dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | TABLET, COATED / ORAL | 49 mg | ||
| cellulose, microcrystalline | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET, COATED / ORAL | 920 mg | ||
| POLYSORBATE 80 | POLYSORBATE 80 | 6OZP39ZG8H | TABLET, COATED / ORAL | 18 mg | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | TABLET, COATED / ORAL | 184 mg | ||
| hypromelloses | HYPROMELLOSE | 3NXW29V3WO | TABLET, COATED / ORAL | 58 mg | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | TABLET, COATED / ORAL | 184 mg | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | TABLET, COATED / ORAL | 184 mg | ||
| titanium dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | TABLET, COATED / ORAL | 49 mg | ||
| hypromelloses | HYPROMELLOSE | 3NXW29V3WO | TABLET, COATED / ORAL | 58 mg | ||
| talc | TALC | 7SEV7J4R1U | TABLET, COATED / ORAL | 320.75 mg | ||
| cellulose, microcrystalline | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET, COATED / ORAL | 920 mg | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | TABLET, COATED / ORAL | 184 mg | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | TABLET, COATED / ORAL | 184 mg | ||
| FD&C BLUE NO. 2 | FD&C BLUE NO. 2 | L06K8R7DQK | TABLET, COATED / ORAL | 24.12 mg | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | TABLET, COATED / ORAL | 184 mg | ||
| povidone | POVIDONE | FZ989GH94E | TABLET, COATED / ORAL | 49.2 mg | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | TABLET, COATED / ORAL | 184 mg | ||
| hypromelloses | HYPROMELLOSE | 3NXW29V3WO | TABLET, COATED / ORAL | 58 mg | ||
| POLYSORBATE 80 | POLYSORBATE 80 | 6OZP39ZG8H | TABLET, COATED / ORAL | 18 mg | ||
| POLYSORBATE 80 | POLYSORBATE 80 | 6OZP39ZG8H | TABLET, COATED / ORAL | 18 mg | ||
| cellulose, microcrystalline | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET, COATED / ORAL | 920 mg | ||
| povidone | POVIDONE | FZ989GH94E | TABLET, COATED / ORAL | 49.2 mg | ||
| talc | TALC | 7SEV7J4R1U | TABLET, COATED / ORAL | 320.75 mg | ||
| hypromelloses | HYPROMELLOSE | 3NXW29V3WO | TABLET, COATED / ORAL | 58 mg | ||
| POLYSORBATE 80 | POLYSORBATE 80 | 6OZP39ZG8H | TABLET, COATED / ORAL | 18 mg | ||
| FD&C BLUE NO. 2 | FD&C BLUE NO. 2 | L06K8R7DQK | TABLET, COATED / ORAL | 24.12 mg | ||
| cellulose, microcrystalline | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET, COATED / ORAL | 920 mg | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | TABLET, COATED / ORAL | 184 mg | ||
| FD&C BLUE NO. 2 | FD&C BLUE NO. 2 | L06K8R7DQK | TABLET, COATED / ORAL | 24.12 mg | ||
| hypromelloses | HYPROMELLOSE | 3NXW29V3WO | TABLET, COATED / ORAL | 58 mg | ||
| POLYSORBATE 80 | POLYSORBATE 80 | 6OZP39ZG8H | TABLET, COATED / ORAL | 18 mg | ||
| hypromelloses | HYPROMELLOSE | 3NXW29V3WO | TABLET, COATED / ORAL | 58 mg | ||
| povidone | POVIDONE | FZ989GH94E | TABLET, COATED / ORAL | 49.2 mg | ||
| cellulose, microcrystalline | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET, COATED / ORAL | 920 mg | ||
| titanium dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | TABLET, COATED / ORAL | 49 mg | ||
| povidone | POVIDONE | FZ989GH94E | TABLET, COATED / ORAL | 49.2 mg | ||
| hypromelloses | HYPROMELLOSE | 3NXW29V3WO | TABLET, COATED / ORAL | 58 mg | ||
| cellulose, microcrystalline | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET, COATED / ORAL | 920 mg | ||
| cellulose, microcrystalline | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET, COATED / ORAL | 920 mg | ||
| FD&C BLUE NO. 2 | FD&C BLUE NO. 2 | L06K8R7DQK | TABLET, COATED / ORAL | 24.12 mg | ||
| povidone | POVIDONE | FZ989GH94E | TABLET, COATED / ORAL | 49.2 mg | ||
| povidone | POVIDONE | FZ989GH94E | TABLET, COATED / ORAL | 49.2 mg | ||
| FD&C BLUE NO. 2 | FD&C BLUE NO. 2 | L06K8R7DQK | TABLET, COATED / ORAL | 24.12 mg | ||
| hypromelloses | HYPROMELLOSE | 3NXW29V3WO | TABLET, COATED / ORAL | 58 mg | ||
| povidone | POVIDONE | FZ989GH94E | TABLET, COATED / ORAL | 49.2 mg | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | TABLET, COATED / ORAL | 184 mg | ||
| talc | TALC | 7SEV7J4R1U | TABLET, COATED / ORAL | 320.75 mg | ||
| hypromelloses | HYPROMELLOSE | 3NXW29V3WO | TABLET, COATED / ORAL | 58 mg | ||
| cellulose, microcrystalline | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET, COATED / ORAL | 920 mg | ||
| cellulose, microcrystalline | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET, COATED / ORAL | 920 mg | ||
| titanium dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | TABLET, COATED / ORAL | 49 mg | ||
| POLYSORBATE 80 | POLYSORBATE 80 | 6OZP39ZG8H | TABLET, COATED / ORAL | 18 mg | ||
| titanium dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | TABLET, COATED / ORAL | 49 mg | ||
| talc | TALC | 7SEV7J4R1U | TABLET, COATED / ORAL | 320.75 mg | ||
| cellulose, microcrystalline | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET, COATED / ORAL | 920 mg | ||
| povidone | POVIDONE | FZ989GH94E | TABLET, COATED / ORAL | 49.2 mg | ||
| titanium dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | TABLET, COATED / ORAL | 49 mg | ||
| POLYSORBATE 80 | POLYSORBATE 80 | 6OZP39ZG8H | TABLET, COATED / ORAL | 18 mg | ||
| povidone | POVIDONE | FZ989GH94E | TABLET, COATED / ORAL | 49.2 mg |
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A075168-001 | NAPROXEN SODIUM | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 1998-07-28 |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | A075168-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 1998-07-28 | 84e616aacf4f… | ||
| 2026-08-18 06:07:40 | 2026-07 | A075168-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 1998-07-28 | caaa826d4ba7… | ||
| 2026-02-19 14:30 UTC | 2026-02 | A075168-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 1998-07-28 | 011fe1cb6892… | ||
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A075168-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 1998-07-28 | 31067a03dcf5… | ||
| 2025-08-23 18:47 UTC | 2025-08 | A075168-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 1998-07-28 | 6a471c1ec25d… | ||
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A075168-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 1998-07-28 | fd3edfee7708… | ||
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A075168-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 1998-07-28 | b8a1b40f171c… | ||
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A075168-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 1998-07-28 | 03ed91905a0d… | ||
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A075168-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 1998-07-28 | 2680178bc6a6… | ||
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A075168-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 1998-07-28 | 5bbf6a4d5a75… | ||
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A075168-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 1998-07-28 | d8e5a09893c0… | ||
| 2024-10-29 15:01 UTC | 2024-10 | A075168-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 1998-07-28 | d06236e962d9… | ||
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A075168-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 1998-07-28 | 79d66fd596c7… | ||
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A075168-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 1998-07-28 | 301d65b070ca… | ||
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A075168-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 1998-07-28 | 1e350fbaab3a… | ||
| 2024-05-31 18:47 UTC | 2024-05 | A075168-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 1998-07-28 | 8072bd15b7f6… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A075168-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 1998-07-28 | 5c6f7cd8ea54… | ||
| 2022-04-08 23:34 UTC | 2022-04 | A075168-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 1998-07-28 | 5d02ea3f76ae… | ||
| 2022-04-04 05:41 UTC | 2022-04 | A075168-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 1998-07-28 | 4b0b4de00fa7… | ||
| 2019-12-13 00:20 UTC | 2019-12 | A075168-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 1998-07-28 | 74a2ff9319b5… | ||
| 2022-03-09 01:35 UTC | 2022-03 | A075168-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 1998-07-28 | bb7c543d1eb4… | ||
| 2021-12-28 21:50 UTC | 2021-12 | A075168-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 1998-07-28 | 782e0a99824c… | ||
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | A075168-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 1998-07-28 | 87673890dc5c… | ||
| 2021-03-12 10:30 UTC | 2021-03 | A075168-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 1998-07-28 | 5aa47cf7b7d7… | ||
| 2020-12-22 03:56 UTC | 2020-12 | A075168-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 1998-07-28 | 8869cabd3fbd… | ||
| 2020-11-12 02:37 UTC | 2020-11 | A075168-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 1998-07-28 | c0c555d07b60… | ||
| 2019-12-14 00:12 UTC | 2019-12 | A075168-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 1998-07-28 | 3f01610625f2… | ||
| 2019-09-15 20:21 UTC | 2019-09 | A075168-001 | NAPROXEN SODIUM | EQ 200MG BASE | TABLET / ORAL | 1998-07-28 | b00525d2431f… | ||
| 2019-07-19 19:46 UTC | 2019-07 | A075168-001 | NAPROXEN SODIUM | EQ 200MG BASE | TABLET / ORAL | 1998-07-28 | ea99ee380514… | ||
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | A075168-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 1998-07-28 | 6a51e52b5d6a… | ||
| 2024-02-18 07:12 UTC | 2024-02 | A075168-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 1998-07-28 | 1c564ffb4f44… | ||
| 2023-12-20 04:57 UTC | 2023-12 | A075168-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 1998-07-28 | ea1830bbd6c7… | ||
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | A075168-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 1998-07-28 | a72a2bbeb626… | ||
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | A075168-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 1998-07-28 | 9b2671bbb829… | ||
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | A075168-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 1998-07-28 | a67488948f0b… | ||
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | A075168-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 1998-07-28 | 3f0d92c62455… | ||
| 2023-05-13 08:27 UTC | 2023-05 | A075168-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 1998-07-28 | 053a50430f4f… | ||
| 2023-01-26 05:58 UTC | 2023-01 | A075168-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 1998-07-28 | 3bdfa0b2c4d7… | ||
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | A075168-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 1998-07-28 | 3a93d1ddd44b… | ||
| 2022-10-28 04:53 UTC | 2022-10 | A075168-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 1998-07-28 | f41ea6bd6efb… |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Naproxen Sodium | NAPROXEN SODIUM | Dr.Reddy's Laboratories Limited | aca5d497-fbc6-464d-2dee-25c50e11bc78 | 2025-06-03 | Warnings | 55111-272-24 55111-273-50 55111-272-50 55111-272-05 55111-273-01 55111-273-24 55111-272-01 55111-273-40 55111-272-02 55111-273-05 55111-273-02 55111-273 55111-272 55111027205 55111027301 55111027350 55111027324 55111027201 55111027224 55111027340 55111027202 55111027302 55111027305 55111027250 45f79372-39c7-ae59-c119-51aece645ae0 aca5d497-fbc6-464d-2dee-25c50e11bc78 |
Adverse event summaries are temporarily unavailable. Other product information remains available.